[go: up one dir, main page]

WO1999053052A3 - Lignees cellulaires srebp-2-deficientes - Google Patents

Lignees cellulaires srebp-2-deficientes Download PDF

Info

Publication number
WO1999053052A3
WO1999053052A3 PCT/DE1999/001143 DE9901143W WO9953052A3 WO 1999053052 A3 WO1999053052 A3 WO 1999053052A3 DE 9901143 W DE9901143 W DE 9901143W WO 9953052 A3 WO9953052 A3 WO 9953052A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell lines
srebp
deficient cell
arterioscelerosis
hypercholesterolaemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE1999/001143
Other languages
German (de)
English (en)
Other versions
WO1999053052A2 (fr
Inventor
Wilhelm Krone
Dirk Mueller-Wieland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUELLER WIELAND DIRK
Original Assignee
MUELLER WIELAND DIRK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MUELLER WIELAND DIRK filed Critical MUELLER WIELAND DIRK
Priority to AU44969/99A priority Critical patent/AU4496999A/en
Priority to EP99927674A priority patent/EP1071778A2/fr
Publication of WO1999053052A2 publication Critical patent/WO1999053052A2/fr
Publication of WO1999053052A3 publication Critical patent/WO1999053052A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des lignées cellulaires eucaryotes SREBP(Sterol Regulatory Element Binding Protein)-2-négatives, leur utilisation par échantillonnage et test des substances, ainsi que des médicaments utilisés pour traiter ou assurer la prophylaxie par ex. de l'hypercholestérolémie, de l'artériosclérose ou de maladies cardiaques coronariennes.
PCT/DE1999/001143 1998-04-16 1999-04-15 Lignees cellulaires srebp-2-deficientes Ceased WO1999053052A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU44969/99A AU4496999A (en) 1998-04-16 1999-04-15 Srebp-2-deficient cell lines
EP99927674A EP1071778A2 (fr) 1998-04-16 1999-04-15 Lignees cellulaires srebp-2-deficientes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19816894A DE19816894C1 (de) 1998-04-16 1998-04-16 SREBP-2-defiziente Zellinien
DE19816894.2 1998-04-16

Publications (2)

Publication Number Publication Date
WO1999053052A2 WO1999053052A2 (fr) 1999-10-21
WO1999053052A3 true WO1999053052A3 (fr) 2000-01-20

Family

ID=7864731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1999/001143 Ceased WO1999053052A2 (fr) 1998-04-16 1999-04-15 Lignees cellulaires srebp-2-deficientes

Country Status (4)

Country Link
EP (1) EP1071778A2 (fr)
AU (1) AU4496999A (fr)
DE (1) DE19816894C1 (fr)
WO (1) WO1999053052A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005295867A (ja) * 2004-04-09 2005-10-27 Japan Science & Technology Agency ２型糖尿病モデルとしての非ヒトトランスジェニック動物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026922A2 (fr) * 1993-05-13 1994-11-24 Board Of Regents, The University Of Texas System Procedes et compositions relatives a des proteines de liaison d'elements regulatoires de sterol

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026922A2 (fr) * 1993-05-13 1994-11-24 Board Of Regents, The University Of Texas System Procedes et compositions relatives a des proteines de liaison d'elements regulatoires de sterol

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BROWN MS UND GOLDSTEIN JL: "The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor", CELL, vol. 89, 2 May 1997 (1997-05-02), NA US, pages 331 - 340, XP002123067 *
SATO R ET AL.: "Sterol-dependent transcriptional regulation of sterol regulatory element-binding protein-2", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 43, 25 October 1996 (1996-10-25), MD US, pages 26461 - 26464, XP002123065 *
STREICHER R ET AL: "SREBP-1 mediates activation of the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-I", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 12, 22 March 1996 (1996-03-22), MD US, pages 7128 - 7133, XP002123066 *

Also Published As

Publication number Publication date
EP1071778A2 (fr) 2001-01-31
DE19816894C1 (de) 2000-03-02
AU4496999A (en) 1999-11-01
WO1999053052A2 (fr) 1999-10-21

Similar Documents

Publication Publication Date Title
EP1420009A3 (fr) Nouveaux dérivés d'acides amines présentant une meilleure activité contre la résistance à plusieurs médicaments
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
HUP9901874A3 (en) Human antibodies binding human tnfalfa, pharmaceutical compositions containing thereof and use thereof
BE2015C026I2 (en) 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
WO1997044063A3 (fr) Conjugues d'acide cis-docosahexanoïque et d'agents pharmaceutiques
AU2525599A (en) Use of at least one protein extract of the moringa genus plant seeds and corresponding cosmetic and/or pharmacological composition
HUP9900657A3 (en) Stable extract of hypericum perforatum l., process for preparing the same and pharmaceutical compositions containing them
EE9700020A (et) Heteroaatomit sisaldavad tsülopentaanpüridüüloksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
NO20004098D0 (no) FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser
DK0751129T6 (da) Substituerede dihydrodibenzo(b,f)azepiner, fremgangsmåde til fremstilling deraf, deres anvendelse i behandlingen af nogle lidelser i centralnervesystemet og farmaceutiske sammensætninger indeholdende disse
WO2000028947A3 (fr) Utilisation d'une substance se liant au recepteur peripherique des benzodiazepines dans le traitement des stress cutanes
DE59813229D1 (de) Stabiler extrakt aus hypericum perforatum l., verfahren zu seiner herstellung und pharmazeutische zubereitungen
EE9700044A (et) Heteroarüüloksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid.
NO20010277L (no) Benzocykloheptener, fremgangsmÕte for fremstilling derav, farmasøytiske preparater inneholdende disse, og deres anvendelse for fremstilling av medikamenter
WO2002091858A8 (fr) Compositions anxiolytiques de marcgraviaceae contenant de l'acide betulinique ou des derives d'acide betulinique et procedes associes
EP0797999A3 (fr) Formulations de protéine d'obésité
AU1575697A (en) Compositions and methods for the treatment and diagnosis of cancer
AU5252698A (en) Therapeutic compositions and methods and diagnostic assays for type ii diabetes involving hnf-1
IL125598A0 (en) Mixtures which may be isolated from eugenia jambolana lamarck their preparation and use of these mixtures and some of their constituents as medications
NO20003662L (no) Syntetiske polysakkarider, fremgangsmÕte for fremstilling derav og farmasøytiske preparater inneholdende slike
ZA97741B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders.
AU2002212769A1 (en) Skin external preparation containing pine pollen or pine pollen extract
NO983472D0 (no) Taxoider, deres fremstilling og farmas°ytiske preparater inneholdende taxoidene
DK0838469T3 (da) 10,13,15-trioxatricyclo(9.2.1 9.6)-pentadecanon-derivater, fremgangsmåde til deres fremstilling og lægemidler indeholdende disse forbindelser
WO2002037122A3 (fr) Toxines de sterol glucoside

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999927674

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09673499

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999927674

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999927674

Country of ref document: EP